Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?-Reference-Cited by-同舟云学术

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Published:2016-07-14 Issue:8 Volume:107 Page:1134-1140
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Banno Eri¹,Togashi Yosuke¹,Nakamura Yu¹,Chiba Masato¹²,Kobayashi Yoshihisa²,Hayashi Hidetoshi¹³,Terashima Masato¹,Velasco Marco A.¹,Sakai Kazuko¹,Fujita Yoshihiko¹,Mitsudomi Tetsuya²,Nishio Kazuto¹

Affiliation:

1. Department of Genome Biology Kindai University Faculty of Medicine Osaka‐Sayama Osaka Japan

2. Department of Thoracic Surgery Kindai University Faculty of Medicine Osaka‐Sayama Osaka Japan

3. Department of Medical Oncology Kindai University Faculty of Medicine Osaka‐Sayama Osaka Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12980

Reference44 articles.

1. EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey

2. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

3. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

4. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Pulmonary Adenocarcinoma Patient with Complex Mutations on EGFR Benefits from Furmonertinib after Acquiring Gefitinib Resistance: A Case Report;Recent Patents on Anti-Cancer Drug Discovery;2024-05

3. Current management of uncommon EGFR mutations in non-small cell lung cancer;Current Problems in Cancer;2024-04

4. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis;The Oncologist;2023-04-28

5. A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations;ESMO Open;2023-04